Miranda Cornet
Miranda Cornet has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A. Colomar
Non-Clinical Development, UCB Biopharma SPRL., Braine l'Alleud, Belgium
1 shared publicationA. Delaunois
Non-Clinical Development, UCB Biopharma SPRL., Braine l'Alleud, Belgium
1 shared publicationAndres Eskjær Jensen
Ellegaard Göttingen Minipigs A/S, Soroe Landevej 302, 4261, Dalmose, Denmark
1 shared publication- Anna Engstrom
Genentech Inc, Translational Safety, South San Francisco, CA, USA
1 shared publication B. O. Depelchin
Non-Clinical Development, UCB Biopharma SPRL., Braine l'Alleud, Belgium
1 shared publication- Beatrice Gauthier
SANOFI, Montpellier, France
1 shared publication
Latest Publications
- 19 May 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 161, 105855
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics
- 19 May 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 161, 105855
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics
- 21 April 2015
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 132 (5) , 337-345
Cardiac safety of lacosamide: the non-clinical perspective
Lacosamide is indicated for the adjunctive treatment of partial-onset seizures in adult patients. Unlike other sodium channel-blocking antiepileptic drugs, lacosamide selectively enhances sodium channel slow inactivation. Potential effects of lacosamide on cardiac sodium channels and their cardiovascular consequences were comprehensively assessed. This manuscript presents the non-clinical cardiac safety profile of lacosamide. Lacosamide was tested in vitro on sodium and L-type calcium currents from isolated human atrial myocytes and on hERG-mediated potassium currents from stably transfected HEK293 cells. Cardiac action potentials were recorded in guinea pig ventricular myocytes. In vivo, hemodynamic and ECG parameters were evaluated in anesthetized dogs and monkeys receiving acute cumulative intravenous doses of lacosamide. Following intravenous dosing with lacosamide, dose-dependent PR and QRS prolongation and ECG abnormalities (loss of P waves, atrioventricular and intraventricular blocks, junctional premature contractions) were observed in anesthetized dogs and monkeys. In vitro, lacosamide reduced human cardiac sodium currents in a concentration-, voltage- and state-dependent manner. Lacosamide reductions in Vmax in guinea pig myocytes were similar to lamotrigine and carbamazepine. Lacosamide showed no relevant inhibitory effects on hERG and L-type calcium channels and did not prolong QTc in vivo. ECG findings in anesthetized animals correlate well with in vitro sodium channel-related effects and are also consistent with those (PR prolongation, first-degree atrioventricular block) reported in healthy volunteers and patients with epilepsy. Both in vivo and in vitro effects were detected from exposure levels 1.5- to 2-fold above those achieved with the maximum-recommended human lacosamide dose (400 mg/day).
- 21 April 2015
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 132 (5) , 337-345
Cardiac safety of lacosamide: the non-clinical perspective
Lacosamide is indicated for the adjunctive treatment of partial-onset seizures in adult patients. Unlike other sodium channel-blocking antiepileptic drugs, lacosamide selectively enhances sodium channel slow inactivation. Potential effects of lacosamide on cardiac sodium channels and their cardiovascular consequences were comprehensively assessed. This manuscript presents the non-clinical cardiac safety profile of lacosamide. Lacosamide was tested in vitro on sodium and L-type calcium currents from isolated human atrial myocytes and on hERG-mediated potassium currents from stably transfected HEK293 cells. Cardiac action potentials were recorded in guinea pig ventricular myocytes. In vivo, hemodynamic and ECG parameters were evaluated in anesthetized dogs and monkeys receiving acute cumulative intravenous doses of lacosamide. Following intravenous dosing with lacosamide, dose-dependent PR and QRS prolongation and ECG abnormalities (loss of P waves, atrioventricular and intraventricular blocks, junctional premature contractions) were observed in anesthetized dogs and monkeys. In vitro, lacosamide reduced human cardiac sodium currents in a concentration-, voltage- and state-dependent manner. Lacosamide reductions in Vmax in guinea pig myocytes were similar to lamotrigine and carbamazepine. Lacosamide showed no relevant inhibitory effects on hERG and L-type calcium channels and did not prolong QTc in vivo. ECG findings in anesthetized animals correlate well with in vitro sodium channel-related effects and are also consistent with those (PR prolongation, first-degree atrioventricular block) reported in healthy volunteers and patients with epilepsy. Both in vivo and in vitro effects were detected from exposure levels 1.5- to 2-fold above those achieved with the maximum-recommended human lacosamide dose (400 mg/day).